Octreotide long-term treatment in patients with portal hypertension: Persistent inhibition of postprandial glucagon response without major changes in renal function

Journal of Hepatology

Volumn 26, Issue 4, 1997, Pages 816-825

  Malesci, Alberto ^a   Tacconi, Milena ^a   Valentini, Angela ^a   Basilico, Mauro ^a   Lorenzano, Elettra ^a   Salerno, Francesco ^a  

^a NONE

Author keywords

glucagon release; glycemic homeostasis; octreotide; portal hypertension; renal function; splanchnic hemodynamics

Indexed keywords

GLUCAGON; GLUCOSE; INSULIN; OCTREOTIDE;

ADULT; AGED; ARTICLE; BLOOD FLOW; BLOOD PRESSURE; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FUNCTION; LIVER CIRRHOSIS; MALE; PORTAL HYPERTENSION; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; UREA BLOOD LEVEL;

EID: 0030953521     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(97)80247-4     Document Type: Article

References (33)

1. Bauer W, Briner U, Doepfner W, Haller R, Huguenin R, Marback P, Petcher TJ, Pless J. SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci. 31:1982;1133-1140.
2. Long RG. Review: long-acting somatostatin analogues. Aliment Pharmacol Ther. 1:1987;191-200.
3. Wahren J, Eriksson LS. The influence of a long-acting somatostatin analogue on spanchnic haemodynamics and metabolism in healthy subjects and patients with liver cirrhosis. Scand J Gastroenterol. 21:1996;103-108. (suppl 119).
4. Eriksson LS, Brundin T, Soderlund C, Wahren J. Haemodynamic effects of a long-acting somatostatin analogue in patients with liver cirrhosis. Scand J Gastroenterol. 22:1987;919-925.
5. Pringle SD, McKee RF, Garden OJ, Lorimer AR, Carter DC. The effect of a long-lasting somatostatin analogue on portal and systemic haemodynamics in cirrhosis. Aliment Pharmacol Ther. 2:1988;451-459.
6. Lin HC, Tsai YT, Lee FY, Lee SD, Hsia HC, Lin WJ, Lo KJ. Hemodynamic evaluation of octreotide in patients with hepatitis B-related cirrhosis. Gastroenterology. 103:1992;229-234.
7. McCormick PA, Biagini MR, Dick R, Greenslade L, Chin J, Cardin F, Wagstaff D, McIntyre N, Burroughs AK. Octreotide inhibits the meal-induced increases in the portal venous pressure of cirrhotic patients with portal hypertension: a double-blind, placebo-controled study. Hepatology. 16:1992;1180-1186.
8. Buonamico P, Sabba C, Garcia-Tsao G, Berardi E, Antonica G, Ferraioli G, Jensen JE, Lerner E, Taylor KJW, Albano O, Groszmann RJ. Octreotide blunts postprandial splanchnic hyperemia in cirrhotic patients: a double-blind randomized echo-doppler study. Hepatology. 21:1995;134-139.
9. Albillos A, Rossi I, Iborra J, Lledo JL, Calleja JL, Barrios C, Garcia P, Escartin P. Octreotide prevents postprandial splanchnic hyperemia in patients with portal hypertension. J Hepatol. 21:1994;88-94.
10. Lee S, Hadengue A, Moreau R, Hillon P, Lebrec D. Postprandial hemodynamic responses in patients with cirrhosis. Hepatology. 8:1988;647-651.
11. Benoit JN, Zimmerman B, Premen AJ, Go VLW, Granger DN. Role of glucagon in the splanchnic hyperemia of chronic portal hypertension. Am J Physiol. 251:1986;G674-G677.
12. Pizcueta MP, Casamitjana R, Bosch J, Rodes J. Decreased systemic vascular sensitivity to norepinephrine in portal hypertensive rats: role of hyperglucagonism. Am J Physiol. 258:1990;G191-G195.
13. Mesh CL, Joh T, Korthuis RJ, Granger DN, Benoit JN. Intestinal vascular sensitivity to vasopressin in portal hypertensive rats. Gastroenterology. 100:1991;916-921.
14. Hwang SJ, Lin HC, Chang CF, Lee FY, Lu CW, Hsia HC, Wang SS, Lee SD, Tsai YT, Lo KJ. A randomized controlled trial comparing octreotide and vasopressin in the control of acute esophageal variceal bleeding. J Hepatol. 16:1992;320-325.
15. Blei AT. Somatostatin analogue: treatment for portal hypertension? Hepatology. 6:1986;1432-1433.
16. Gines A, Salmeron JM, Gines P, Jimenez W, Salo J, Piera C, Claria J, Rivera F, Arroyo V, Rodes J. Effects of somatostatin on renal function in cirrhosis. Gastroenterology. 103:1992;1868-1874.
17. Prediction of the first variceal hemorrage in patients with cirrhosis of the liver and esophageal varices. A prospective multicenter study. N Engl J Med. 319:1988;993-989.
18. Tornebrandt K, Nobin A, Owman CH. Contractile and dilatory action of neuropeptides on isolated human mesenteric blood vessels. Peptides. 8:1987;251-256.
19. Kravetz D, Bosch J, Arderiu MT, Pizcueta MP, Casamitjana R, Rivera F, Rodes J. Effects of somatostatin on splanchnic hemodynamics and plasma glucagon in portal hypertensive rats. Am J Physiol. 254:1988;G322-G328.
20. Cerini R, Lee SS, Hadengue A, Koshy A, Girod C, Lebrec D. Circulatory effects of somatostatin analogue in two conscious models of portal hypertension. Gastroenterology. 94:1988;703-708.
21. Sieber CC, Mosca PG, Groszmann RJ. Effect of somatostatin on mesenteric vascular resistance in normal and portal hypertensive rats. Am J Physiol. 262:1992;G274-277.
22. Premen AJ, Hall JE, Smith MJ. Postprandal regulation of renal hemodynamics: role of pancreatic glucagon. Am J Physiol. 248:1985;F656-F662.
23. Rodriguez-Perez F, Albillos A, Groszmann RJ. Octreotide improves renal function, total exchangeable sodium and peripheral hemodynamics in cirrhotic patients with ascites. Gastroenterology. 104:1993;A980. (Abstracts).
24. Wong F, Logan A, Blendis L. Hyperinsulinemia in preascitic cirrhosis: effects on systemic and renal hemodynamics, sodium homeostasis, forearm blood flow, and sympathetic nervous activity. Hepatology. 23:1996;414-422.
25. Rizza R, Verdonk C, Miles J, Service J, Haymond M, Gerich. Somatostatin does not cause sustained fasting hyperglycemia in man. J Horm Metab Res. 11:1979;643-644.
26. Mountokalakis T, Kallivretakis N, Mayopoulou-Symvoulidou D, Karvountzis G, Tolis G. Enhancement of renal function by a long-acting somatostatin analogue in patients with decompensated cirrhosis. Nephrol Dial Transplant. 3:1988;604-607.
27. Albillos A, Colombato LA, Lee FY, Groszmann J. Octreotide ameliorates vasodiatation and Na_retention in portal hypertensive rats. Gastroenterology. 104:1993;575-579.
28. Tulassay T, Tulassay Z, Rascher W, Szucs L, Seyberth HW, Nagy I. Effect of somatostatin on kidney function and vasoactive hormone systems in healthy subjects. Klin Wochenschr. 69:1991;486-490.
29. Reubi JC, Horisberger U, Studer UE, Waser B, Laissue JA. Human kidney as target for somatostatin: high affinity receptors in tubules and vasa recta. J Clin Endocrinol Metab. 77:1993;1323-1328.
30. Berthold H, del Pozo E. Antidiuretic effect of Sandostatin (SMS 201-995) in healthy volunteers. Acta Endocrinologica. 120:1989;708-714.
31. Ricci GL, Fevery J. Somatostatin inhibits the effect of secretin on bile flow and on hepatic bilirubin transport in the rat. Gut. 30:1989;1266-1269.
32. Hanks JB, Kortz WJ, Andersen DK, Jones RS. Somatostatin suppression of canine fasting bile secretion. Gastroenterology. 84:1983;130-137.
33. Lin HC, Tsai YT, See SD, Lee FY, Hsia HC, Meng HC, Wang SS, Lo KJ. Octreotide decreases liver metabolic activity in patients with hepatitis B surface antigen-positive cirrhosis. Clin Pharmacol Ther. 52:1992;134-138.